Note | |
| |
Entity | Hepatocellular carcinoma |
Note | Lin28B expression is more frequently noted in high-grade hepatocellular carcinoma with high alpha-fetoprotein levels. Knockdown of Lin28B by RNA interference in the HCC cell line suppressed proliferation in vitro and reduced in vivo tumor growth in NOD/SCID mice. In contrast, overexpression of Lin28B in the HCC cell line enhanced tumorigenicity. Overexpression of Lin28B also induced epithelial-mesenchymal transition in HA22T cells and hence, invasion capacity. |
| |
| |
Entity | Colorectal cancer |
Note | Lin28B is overexpressed in colorectal cancer. It promotes cell migration, invasion and transforms immortalized colonic epithelial cells. In addition, constitutive LIN28B expression increases expression of intestinal stem cell markers LGR5 and PROM1 in the presence of let-7 restoration. |
| |
| |
Entity | Ovarian cancer |
Note | Lin28B is overexpressed in high grade serous ovarian cancer. Pleomorphism in Lin28B promoter region is associated with susceptibility to epithelium ovarian cancer. Patients with high Lin28B ovarian cancer had shorter progression-free and overall survival than those with low Lin28B ovarian cancer. |
| |
| |
Entity | Age at menarche |
Note | A sequence variation in Lin28B is identified as the SNP most significant associated with age at menarche in one genome wide study. Besides, a meta-analysis of 32 genome-wide association studies in 87802 women found polymorphism of Lin28B is strongly associated with age at menarche. Knockout mice of Lin28B also show delay in puberty onset. |
| |
| |
Entity | Body height |
Note | A LIN28B SNP, rs314277, is associated with final body height. |
| |
Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. |
He C, Kraft P, Chen C, Buring JE, Pare G, Hankinson SE, Chanock SJ, Ridker PM, Hunter DJ, Chasman DI. |
Nat Genet. 2009 Jun;41(6):724-8. Epub 2009 May 17. |
PMID 19448621 |
|
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. |
Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ; Australian Ovarian Cancer Study Group, Pearson RB, Borresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD. |
PLoS One. 2011 Apr 13;6(4):e18064. |
PMID 21533284 |
|
Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. |
Heo I, Joo C, Cho J, Ha M, Han J, Kim VN. |
Mol Cell. 2008 Oct 24;32(2):276-84. |
PMID 18951094 |
|
LIN28B promotes colon cancer progression and metastasis. |
King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, Rustgi AK. |
Cancer Res. 2011 Jun 15;71(12):4260-8. Epub 2011 Apr 21. |
PMID 21512136 |
|
LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. |
King CE, Wang L, Winograd R, Madison BB, Mongroo PS, Johnstone CN, Rustgi AK. |
Oncogene. 2011 May 30. [Epub ahead of print] |
PMID 21625210 |
|
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. |
Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, Preti M, Menato G, Yu H. |
Eur J Cancer. 2009 Aug;45(12):2212-8. Epub 2009 May 26. |
PMID 19477633 |
|
Lin28 promotes transformation and is associated with advanced human malignancies. |
Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. |
Nat Genet. 2009 Jul;41(7):843-8. Epub 2009 May 31. |
PMID 19483683 |
|